Skip to main content
PLOS One logoLink to PLOS One
. 2015 Mar 13;10(3):e0119598. doi: 10.1371/journal.pone.0119598

Activity Prediction and Molecular Mechanism of Bovine Blood Derived Angiotensin I-Converting Enzyme Inhibitory Peptides

Ting Zhang 1, Shaoping Nie 2, Boqun Liu 1, Yiding Yu 1, Yan Zhang 1, Jingbo Liu 1,*
Editor: Dulce Elena Casarini3
PMCID: PMC4358945  PMID: 25768442

Abstract

Development of angiotensin I-converting enzyme (ACE, EC 3.4.15.1) inhibitory peptides from food protein is under extensive research as alternative for the prevention of hypertension. However, it is difficult to identify peptides released from food sources. To accelerate the progress of peptide identification, a three layer back propagation neural network model was established to predict the ACE-inhibitory activity of pentapeptides derived from bovine hemoglobin by simulated enzyme digestion. The pentapeptide WTQRF has the best predicted value with experimental IC50 23.93 μM. The potential molecular mechanism of the WTQRF / ACE interaction was investigated by flexible docking.

Introduction

Hypertension is a risk factor for cardiovascular diseases including coronary heart disease, peripheral artery disease and stroke. [1, 2] Recently, several food-derived bioactive peptides have been found playing a significant role in decreasing blood pressure. Therefore, more and more attention has been paid to peptides from food sources with antihypertensive activity. [3]

Most of the antihypertension peptides regulate blood pressure by inhibiting the activity of angiotensin I-converting enzyme (ACE, EC.3.4.15.1). ACE is a zinc- and chloride- dependent metallopeptidase, which belongs to the M2 family of zinc metallopeptidases. [4, 5] It converts angiotensin I to angiotensin II (a potent vasoconstrictor) as well as inactivates the vasodilator bradykinin. [6] ACE plays a crucial role in the renin-angiotensin system (RAS), which is well known for its regulation of blood pressure and fluid homeostasis. [7, 8] Nowadays, inhibitors of ACE have been considered as first-line therapy for hypertension. [9, 10] It has been reported that a number of bioactive peptides, which derived from food sources, have ACE-inhibitory activity. Chibuike C. Udenigwe [11] summarized the major approaches in bioactive peptides research as the classical approach, the bioinformatics approach and the integrated approach. This classification is also suitable for ACE-inhibitory peptides.

The classic approach is the most widely used method for the discovery of ACE-inhibitory peptides from food proteins, involving peptides production (solvent extraction, enzyme hydrolysis, and microbial fermentation), purification (membrane-based separation and chromatography techniques) and identification (mass spectrometry methods). There are a number of ACE-inhibitory peptides derived from different food sources and obtained by the classic approach. For instance, ACE-inhibitory peptides derived from soy protein such as DLP, DG, IA, ILAGNQ, FFL, IYLL, VMDKPQG, IFL, WL, TPRVF, YVVFK, PNNKPFQ, EDENNPFYLR, NWGPLV, IPPGVPYWT, VLIVP, LAIPVNKP, LPHF, SPYP and WL, were found in published articles. [1217] In wheat germ hydrolysates, 16 peptides [18] with the IC50 value of less than 20 μM, composed of 2–7 amino acid residues were identified. And IAP [19] was identified in wheat gliadin hydrolysates. In pork meat hydrolysates digested by in vitro gastrointestinal digestion, 12 peptides were identified. [20] Also, in beef rump (biceps femoris) hydrolysates, Jang and Lee [21] identified VLAQYK.

In order to circumvent some challenges of the classical approach, the bioinformatics approach has been recently applied towards the discovery of ACE-inhibitory peptides encrypted in food proteins. This approach was recently used to study the distribution of ACE-inhibitory peptides within the primary structure of typical food proteins. [22]

Following the identification of bioactive peptides from protein sets by bioinformatics in databases populated following the classical approach, the remainder of the purportedly “inactive” peptides can be analyzed in silico to identify structural patterns that have previously been associated with known bioactivities. [11]

Moreover, the strengths of each approach can be combined as deemed fit to enhance the discovery and use of ACE-inhibitory peptides. Bioinformatics software can be used to simulate proteolytic specificities of enzymes in order to establish the peptide database in silico. [11] Quantitative structure-activity relationship (QSAR) studies are widely undertaken for modeling the bioactivities such as the bioactivity of ACE-inhibitory peptides [2226] and the sweetness of compounds [27]. Neural network, as a kind of artificial intelligence, has been applied to modeling non-linear systems, simulating the chaos bioprocess and predicting the results. It turns out to have higher modeling accuracy and generalization capacity [28] and becomes a potentially effective tool in modeling the QSAR.

Bovine blood, as a by-product generated in great volume in industrial abattoirs, gives rise to several possibilities for their recovery and use. The use of bovine blood as a food component has been widely reported due in part to their high nutritional value and there are many studies have recently demonstrated that bovine blood proteins can be used to obtain bioactive peptides. This is important because it gives an added value to bovine blood. A number of bioactive peptides released from bovine hemoglobin hydrolysates have been reported. [2932] It is a highly desirable but difficult task to identify bovine blood derived peptides. In this aspect, prediction model would be a useful technique to highlight potential ACE-inhibitory peptides identification.

It was found that ACE has two homologous domains (the N-domain and the C-domain), each containing an active center. [33] The C-domain of ACE has been proved to be the dominant angiotensin-I converting site, which has a conserved HEXXH zinc-binding motif, for controlling blood pressure and serving cardiovascular functions. [34, 35] If inhibitory peptides occupied the active site of the C-domain of ACE and bound to specific amino acid residues, ACE will lose its activity. Therefore, it is possible to reveal the ACE inactivation mechanisms by analyzing the structural consequences of ACE-inhibitor interactions. [34]

In this study, we established a database of potential pentapeptides derived from bovine hemoglobin by simulated enzyme digestion, and a prediction model of ACE-inhibitory pentapeptides by back propagation neural network (BPNN). The peptide with best predictive value was synthesized and its IC50 of ACE was measured. We also sought to elucidate the potential molecular mechanism of how the peptide with best predictive value exerts its ACE-inhibitory effects by automated molecular docking.

Materials and Methods

Materials and Chemicals

Angiotensin converting enzyme from rabbit lung, hippuryl-L-histidyl-L-leucine, hippuric acid and HPLC grade acetonitrile, trifluoroacetic acid were purchased from Sigma Chemical Co. (St. Louis, Mo., U.S.A.). All the other reagents were analytical grade.

Dataset

A total of 24 unique pentapeptides were collected from published articles with IC50 of ACE from 0.00948μM to 848 μM in Table 1. [16, 3648] Due to the wide range of IC50 value, the negative logarithm of IC50 (pIC50) was used ranging from-2.928 to 2.023.

Table 1. The IC50 (μM) of ACE of 24 pentapeptides as taken from literature.

No. Sequence IC50 No. Sequence IC50
1 ARHPH 0.0156 13 MRWRD 2.1
2 DIGYY 3.4 14 RINKK 0.0183
3 DKIHP 113.1 15 RYLGY 0.71
4 DYVGN 0.72 16 SLPQN 0.00948
5 ERYPI 8.76 17 TVVPG 2.2
6 EVPKA 324.77 18 TYKEE 0.0186
7 IKYGD 4.5 19 TYLGS 0.86
8 KDERF 848 20 VKQGF 20.3
9 KDYRL 26.5 21 VLIVP 1.69
10 LDIQK 27.6 22 WVPSV 0.501
11 LPYPY 28.9 23 YTAGV 23.38
12 LVQGS 43.7 24 YVVFK 44

Molecular Descriptors Calculation

Ten molecular descriptors were calculated for analogs of peptides including structural, spatial, thermodynamic and electronic. Structural descriptors included the number of rotatable bond (Rotbond), the number of hydrogen bond acceptor (H bond acceptor), the number of hydrogen bond donor (H bond donor), the number of ring (Ring) and the number of arcomatic ring (AR). [4951] The molecular fractional polar surface area (PSA) [52] was used as spatial descriptor. The thermodynamic descriptors were taken to describe the hydrophobic character (ALog P: logarithm of the partition coefficient in octanol / water and Log D: logarithm of the partition coefficient in octanol / water in pH 7.4) and refractivity (MR: molar refractivity). [49] The atomic polarizabilities (Apol) were calculated as electronic descriptors. [50] Peptide structures were generated by Accelrys Discovery Studio 3.5 software (Accelrys Inc., San Diego, USA) and the energy was minimized with CHARMm program using steepest descent and conjugate gradient techniques. All descriptors were calculated by calculate molecular properties protocol.

Modeling by Back-Propagation Neural Network (BPNN)

To construct a BPNN, the Levenberg-Marquardt algorithm [53] was used to train the network. With all data normalized, the descriptors and the pIC50 of dataset were introduced as input and output values, respectively. In order to avoid overfitting, the dataset was randomly classified for training, validation, and test sets. To verify the suitable number of nodes in hidden layer and transfer function, the mean square error (MSE) and pearson correlation coefficient (R) of each BPNN model were calculated.

Simulated Enzyme Digestion and BPNN Prediction

Pepsin and trypsin degrade food proteins into peptides, which are critical in human digestion of protein. The online software Peptide Cutter (http://web.expasy.org/peptide_cutter/) can predict potential cleavage sites cleaved by proteases, including pepsin and trypsin, in a certain protein sequence. As hemoglobin is composed of four poly peptide subunits, two α and two β, we used Peptide Cutter to predict the potential pentapeptides of subunit α (accession number, P01966) and β (accession number, P02070), respectively. All pentapeptides were described by descriptors mentioned above. And then, put the normalized descriptors into the best BPNN model as input data to predict the ACE-inhibitory activity.

Peptide Synthesis

The peptide was synthesized (ChinaPeptides Co. Ltd., Shanghai, China) by the solid phase procedure peptide using FMOC protected amino acids synthesis. The purity (95%) and the molecular masses of the peptides were determined by HPLC and mass spectrometry.

Assay for ACE-Inhibitory Activity

The ACE-inhibitory activity of the peptide with best predict value was measured according to Liu, et al. [54]

Docking

The 3-D structure of human ACE was imported from Protein Data Bank (1O8A.pdb, a crystal structure of human ACE). The structure of peptide was generated by DS and the energy was minimized with CHARMm program. Automated molecular docking was performed using the flexible docking tool of DS software in the presence of cofactors (zinc and chloride ions). The binding site with a radius of 15 Å and a coordinates x: 45.0463, y: 38.6842, z: 45.8268. Evaluation of the molecular docking was performed according to the scores and total potential energy in order to obtain the best pose of peptide. The DS software was used to identify the hydrogen bonds as well as the hydrophobic, hydrophilic, electrostatic and coordination interactions between residues present within ACE active site.

Results and Discussion

Structural Features Analysis

Most of the ACE-inhibitory peptides derived from egg white hydrolysates in our lab previously [5557] were pentapeptides. Therefore, we are interested in ACE-inhibitory pentapeptide and try to build a prediction model based on a pentapeptides database (Table 1). It shows that 75% of the pentapeptides taken from literature have 1 or 2 hydrophobic amino acid residues. A half of these pentapeptides contain aromatic or hydrophobic amino acid residues at the C-terminus, which are beneficial to ACE-inhibitory activity. [24] In addition, 66.67% of these pentapeptides contain hydrophilic amino acid residues in the second amino acid residues from the C-terminus. The aforementioned common structural features can be used to instruct ACE-inhibitory peptides’ design.

The molecular descriptor (Tables 2, 3) calculation is a logic and mathematical procedure which converts the chemical information of a molecule into some useful data. Most of the number ranges of descriptors of Pentapeptides derived from hemoglobin simulated enzyme digestion included in the scope of the reported pentapeptides, except the molar refractivity of GHGAK. The range of MR of reported pentapeptides is 111.291 to 186.874, while the GHGAK is 107.89. Nevertheless, the predicted IC50 of GHGAK is the fourth lowest among the seven hemoglobin pentapeptides, because the BPNN is a nonlinearity model, leading to a nonlinear relationship between the input and the output.

Table 2. Descriptors of 24 peptides.

No. ALog P MR Apol Log D Rot bond Ring AR H bond acceptor H bond donor PSA
1 -3.40648 150.01 21,842.80 -5.211 16 3 2 8 9 0.472
2 -0.5315 148.186 23,371.50 -3.62 17 2 2 10 7 0.417
3 -1.57883 140.478 21,007.90 -6.343 18 2 1 9 6 0.43
4 0.1427 125.13 20,031.40 -6.645 16 1 1 10 7 0.496
5 -4.17411 162.498 24,053.20 -4.59 19 2 1 9 8 0.43
6 -1.75544 123.385 18,340.80 -6.673 16 1 0 8 5 0.423
7 1.17668 137.363 21,169.30 -5.804 19 1 1 9 7 0.438
8 -7.64934 157.324 24,572.40 -9.119 24 1 1 10 9 0.492
9 -0.97576 165.622 24,679.50 -6.381 23 1 1 9 10 0.46
10 -1.4409 141.829 20,908.70 -6.554 22 0 0 9 7 0.444
11 -0.18578 165.819 24,392.10 -0.486 13 4 2 8 5 0.32
12 2.40026 116.474 16,937.50 -5.206 16 0 0 8 7 0.459
13 -1.4177 186.874 28,111.80 -5.953 24 2 2 9 12 0.502
14 4.6319 160.264 22,613.60 -7.87 25 0 0 7 11 0.482
15 1.46736 169.636 25,104.30 -2.379 19 2 2 8 10 0.419
16 0.616643 127.519 18,710.70 -6.491 16 1 0 9 7 0.486
17 1.08715 111.291 15,909.40 -3.97 11 1 0 7 5 0.392
18 -6.51692 146.046 23,291.50 -8.625 22 1 1 12 8 0.483
19 2.27823 127.141 19,082.70 -4.319 15 1 1 9 8 0.439
20 0.263857 141.365 20,960.90 -5.071 19 1 1 7 7 0.418
21 -0.2278 137.092 18,644.10 -0.405 14 1 0 6 4 0.299
22 -10.8299 147.072 21,425.80 -1.896 13 3 2 7 6 0.354
23 -0.94115 120.919 18,224.60 -3.266 13 1 1 8 7 0.424
24 -1.6435 168.555 24,814.30 -0.956 19 2 2 7 7 0.34

Table 3. Pentapeptides derived from hemoglobin simulated enzyme digestion.

AAWGK AHRYH FTPVL GHGAK PTTKT TSKYR WTQRF
Proteases Trypsin Pepsin Pepsin Trypsin Pepsin Pepsin Pepsin
Subunit α β β α α α β
ALogP -4.704 -5.548 -1.547 -7.589 -7.283 -6.927 -3.789
MR 130.843 168.635 145.081 107.89 125.207 157.139 186.729
Apol 19,654.10 25,184.50 20,818.60 16,291.60 18,110.90 23,078.30 27,793.80
LogD -4.702 -4.691 -1.54 -6.806 -7.28 -6.915 -2.911
Rot bond 15 19 14 15 16 21 21
Ring 2 3 2 1 1 1 3
AR 2 3 1 1 0 1 3
H bond acceptor 6 9 7 7 9 9 8
H bond donor 7 11 5 7 9 12 11
PSA 0.414 0.47 0.326 0.487 0.46 0.492 0.439
BPNN output 0.5093 0.7990 0.4534 0.4983 0.2890 0.3204 0.8501
Predicted IC50 (μM) 2.5513 0.0938 4.8240 2.8916 31.4255 21.9784 0.0524

BPNN model Building

There were three layers in the BPNN model (input layer, hidden layer and output layer), while the number of nodes in hidden layer was not certain. So that we trained BPNN models with different number of nodes in hidden layer and different transfer functions to obtain the suitable model structure (Fig. 1, Fig. 2 and S1 Table, S2 Table). For the log-sigmoid & purelin transfer function, the highest MSE appears when the number of hidden layers is twelve. However, in terms of the tan-sigmoid & tan-sigmoid transfer function, the MSE is relatively low when the number of hidden layers is between four and fifteen, and the lowest MSE (0.0587 ± 0.0351) is obtained when it reaches seven. Besides, seven hidden layers with the log-sigmoid & purelin transfer function bring the highest determination coefficient (square of R, 0.3819 ± 0.2781). Therefore, we decided to select 10–7–1 as the topological structure of BPNN and the tan-sigmoid transfer function as the transfer function between both input layer & hidden layer and hidden & output layer. To improve the accuracy of the final model, we set the aim as R > 0.9 and trained 10–7–1 BPNN with tan-sigmoid transfer function & tan-sigmoid transfer function several times. The MSE and correlation coefficients of this model were in acceptable ranges as shown in Table 4. These correlation coefficients indicate that there is a strong correlation between the predicted and experimental result and the MSE (0.162) is acceptable. The plots of experimental versus predicted values (Fig. 3) confirmed the discussed results. Hence, we chose this one as the final model. To our knowledge, it was the first time applying BPNN to predict the IC50 of ACE of pentapeptide. In our previous work [58], a BPNN model was built to predict the IC50 of ACE of tripeptide. The MSE of the tripeptide model (0.2148) is higher than this pentapeptide model (0.0162). Meanwhile, the R of the tripeptide model (0.854) was less than this new model (0.9176). These differences possibly resulted from the difference of descriptors.

Fig 1. The MSE of different structure of BPNN models.

Fig 1

Fig 2. The coefficient of determination (square of pearson correlation coefficient) of different structure of BPNN models.

Fig 2

Table 4. MSE and correlation coefficients of final BPNN model.

MSE Pearson Kendall Spearman
0.0162 0.9176** 0.7536** 0.8887**

** Significant difference is p<0.01.

Fig 3. Predicted versus experimental plots for BPNN model.

Fig 3

Activity Prediction and Experimental Verification

After simulated enzyme digestion of hemoglobin, seven pentapeptides among all the cleavage fragments were obtained. The descriptor calculated value and the predicted IC50 were shown in Table 3. The pentapeptide WTQRF and AAWGK contain two or three hydrophobic amino acid residues, which is in agreement with the common features of the 24 reported pentapeptides, and show a low predicted IC50. The AHRYH, WTQRF and FTPVL contain hydrophpbic or aromatic amino acid residues in the C- terminus which contribute to ACE inhibition. For the second amino acid residues from C-terminus, the PTTKT, WTQRF and AAWGK contain hydrophilic amino acid residues, which also match the common features of the 24 reported pentapeptides. Obviously, WTQRF conforms to all the aforementioned common features. It include three hydrophilic amino acid residues (Thr, Gln, Arg) and two hydrophobic amino acid residues with aromatic (Trp) / heterocyclic (phe) ring in their side chain. It molecular weight is 736.83 g / mol. The hydrophobic amino acid residues in both of the N- and C- terminus as well as the hydrophilic amino acid residues in the second amino acid residues from C-terminus may make main contribution to ACE inhibition. The result of predicted IC50 indicated that the peptide WTQRF has the best inhibitory activity of ACE. The experimental IC50 of WTQRF is 23.93 μM, which is similar to a pentapeptide identified from egg white protein in our lab before (RVPSL, IC50 20 μM). [54] The difference between predicted and experimental IC50 may bring from data normalization.

Molecular Docking

Interactions between ACE and inhibitor are fundamental to ACE-inhibitory processes. In this work, docking is used to predict the preferred orientation of WTQRF to ACE when they bound to each other to form a stable complex. The free energy of binding represents the binding affinity between ACE and WTQRF. The molecular docking study of WTQRF presenting within the ACE catalytic site in the presence of the cofactor showed the best pose with potential binding energy:- 749.747 kj / mol. It is indicated that the ligand bind tightly to the receptor and the ACE-WTQRF complex is stable. As we know, ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules. The best pose of WTQRF was stabilized mainly by hydrophobic and hydrophilic interactions (Fig. 4), electrostatic interactions (Electrostatic energy:- 154.728 kj / mol; Van der Waals energy:- 898.743 kj / mol) and hydrogen bond (Table 5).

Fig 4. WTQRF binding with the active site of ACE, the conformation extracted from docking result.

Fig 4

Table 5. Hydrogen bonds observed between ACE and the best docking pose of WTQRF.

Donor-Acceptor ARG522:HH12—WTQRF:O53 ARG522:HH22—WTQRF:O53 WTQRF:H54—ARG522:NH2 WTQRF:H92—TYR360:OH
Distance (Å) 1.36 1.86 2.44 1.76

The hydroxyl group of Tyr 360, the guanidine and the ɛ-amino group of Arg 522 showed significant importance of the binding between WTQRF and ACE by hydrogen bond. The docking result suggested that WTQRF contact with residues Met 223, Ala 354, 356, Tyr 360, 394, Phe 391, Pro 407, 519, Val 518 by hydrophobic interactions and with residues His 353, 383, 387, 413, Ser 355, 517, Arg 402, 522, Glu 384, 403, 411, Asn 406, Val 518 by hydrophilic interactions. The active site of ACE was constituted of a zinc ion and a HEXXH…E motif, including His 383, Glu 384, His 387 on helix α 13 and Glu 411 on helix α 14. [34, 59] The WTQRF were positioned to interact with the HEXXH…E motif. Furthermore, the interactions between inhibitors and Zn2+ at the ACE active site also play a significant role in modulating catalysis. [60] It is believed that the shorter distance between the Zn2+ and the carbonyl oxygen of the peptide, the greater the degree of ACE inhibition. [34]

Conclusion

In this present work, a back propagation neural network model was built to predict the IC50 of ACE of pentapeptides. The topological structure was 10–7–1 and the transfer function was tan-sigmoid transfer function & tan-sigmoid transfer function. We also built a database of potential pentapeptides derived from bovine hemoglobin by simulated enzyme digestion and found that WTQRF has the highest predictive value with experimental IC50 23.93 μM. The molecular docking result indicated that Tyr 360 and Arg 522 gave a significantly contribution to the stabilization between WTQRF and ACE. The result also demonstrated that the short distance between the Zn2+ and the carbonyl oxygen of the peptide are desirable to the ACE-inhibitory activity. The enzyme kinetics investigation as well as docking and molecular dynamics simulation analysis will be our further study.

Supporting Information

S1 Table. The MSE of different structure of BPNN model.

(DOC)

S2 Table. The coefficient of determination (square of pearson correlation coefficient) of different structure of BPNN models.

(DOC)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by the Grant 31271907 and 31471597 of the National Natural Science Foundation of China, the Specialized Research Fund for the Doctoral Program of Higher (No. 20130061110088), and the Project of National Key Technology Research and Development Program for the 12th Five-year Plan (NO. 2012BAD33B03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Hernandez-Ledesma B, del Mar Contreras M, Recio I. Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv Colloid Interface Sci. 2011;165(1):23–35. 10.1016/j.cis.2010.11.001 [DOI] [PubMed] [Google Scholar]
  • 2. Lu J, Sawano Y, Miyakawa T, Xue Y-L, Cai M-Y, Egashira Y, et al. One-Week Antihypertensive Effect of Ile-Gln-Pro in Spontaneously Hypertensive Rats. J Agric Food Chem. 2011;59(2):559–563. 10.1021/jf104126a [DOI] [PubMed] [Google Scholar]
  • 3. Vermeirssen V, Camp JV, Verstraete W. Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr. 2004;92:357–366. [DOI] [PubMed] [Google Scholar]
  • 4. Sturrock ED, Natesh R, van Rooyen JM, Acharya KR. Structure of angiotensin I-converting enzyme. Cell Mol Life Sci. 2004;61(21):2677–2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Turner AJ, Hooper NM. The angiotensin—converting enzyme gene family genomics and pharmacology. TRENDS PHARMACOL SCI. 2002;23(4):177–183. [DOI] [PubMed] [Google Scholar]
  • 6. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res. 2006;98(7):887–896. [DOI] [PubMed] [Google Scholar]
  • 7. Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004;43(27):8718–8724. [DOI] [PubMed] [Google Scholar]
  • 8. Lavoie JL, Sigmund CD. Minireview: Overview of the Renin-Angiotensin System—An Endocrine and Paracrine System. Endocrinology. 2003;144(6):2179–2183. [DOI] [PubMed] [Google Scholar]
  • 9. Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res. 2010;33(1):11–21. 10.1038/hr.2009.184 [DOI] [PubMed] [Google Scholar]
  • 10. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern Med. 1994;154(5):513–523. [PubMed] [Google Scholar]
  • 11. Udenigwe CC. Bioinformatics approaches, prospects and challenges of food bioactive peptide research. Trends Food Sci Technol. 2014;(36):137–143. [Google Scholar]
  • 12. Wu J, Ding X. Characterization of inhibition and stability of soy-protein-derived angiotensin I-converting enzyme inhibitory peptides. FOOD RES INT. 2002;35(4):367–375. [Google Scholar]
  • 13. Chen JR, Okada T, Muramoto K, Suetsuna K, Yang S-C. Identification of Angiotensin I-Converting enzyme inhibitory peptides derived from the peptic digest of soybean protein. J Food Biochem. 2002;26(6):543–554. [Google Scholar]
  • 14. Kuba M, Tanaka K, Tawata S, Takeda Y, Yasuda M. Angiotensin I-converting enzyme inhibitory peptides isolated from tofuyo fermented soybean food. Biosci Biotech Bioch. 2003;67(6):1278–1283. [DOI] [PubMed] [Google Scholar]
  • 15. Kodera T, Nio N. Identification of an Angiotensin I-converting Enzyme Inhibitory Peptides from Protein Hydrolysates by a Soybean Protease and the Antihypertensive Effects of Hydrolysates in 4 Spontaneously Hypertensive Model Rats. J Food Sci. 2006;71(3):C164–C173. [Google Scholar]
  • 16. Mallikarjun Gouda K, Gowda LR, Rao AA, Prakash V. Angiotensin I-converting enzyme inhibitory peptide derived from glycinin, the 11S globulin of soybean (Glycine max). J Agric Food Chem. 2006;54(13):4568–4573. [DOI] [PubMed] [Google Scholar]
  • 17. Kuba M, Tana C, Tawata S, Yasuda M. Production of angiotensin I-converting enzyme inhibitory peptides from soybean protein with Monascus purpureus acid proteinase. PROCESS BIOCHEM. 2005;40(6):2191–2196. [Google Scholar]
  • 18. Matsui T, Li CH, Osajima Y. Preparation and characterization of novel bioactive peptides responsible for angiotensin I-converting enzyme inhibition from wheat germ. J Pept Sci. 1999;5(7):289–297. [DOI] [PubMed] [Google Scholar]
  • 19. Motoi H, Kodama T. Isolation and characterization of angiotensin I-converting enzyme inhibitory peptides from wheat gliadin hydrolysate. Nahrung. 2003;47(5):354–358. [DOI] [PubMed] [Google Scholar]
  • 20. Escudero E, Sentandreu MA, Arihara K, Toldra F. Angiotensin I-converting enzyme inhibitory peptides generated from in vitro gastrointestinal digestion of pork meat. J Agric Food Chem. 2010;58(5):2895–2901. 10.1021/jf904204n [DOI] [PubMed] [Google Scholar]
  • 21. Jang A, Lee M. Purification and identification of angiotensin converting enzyme inhibitory peptides from beef hydrolysates. Meat Sci. 2005;69(4):653–661. 10.1016/j.meatsci.2004.10.014 [DOI] [PubMed] [Google Scholar]
  • 22. Gu Y, Majumder K, Wu J. QSAR-aided in silico approach in evaluation of food proteins as precursors of ACE inhibitory peptides. FOOD RES INT. 2011;44(8):2465–2474. [Google Scholar]
  • 23. Wu J, Aluko RE. Quantitative structure-activity relationship study of bitter di- and tri-peptides including relationship with angiotensin I-converting enzyme inhibitory activity. J Pept Sci. 2007;13(1):63–69. [DOI] [PubMed] [Google Scholar]
  • 24. Wu J, Aluko RE, Nakai S. Structural Requirements of Angiotensin I-Converting Enzyme Inhibitory Peptides: Quantitative Structure-Activity Relationship Modeling of Peptides Containing 4–10 Amino Acid Residues. QSAR Comb Sci. 2006;25(10):873–880. [DOI] [PubMed] [Google Scholar]
  • 25. Majumder K, Wu J. A new approach for identification of novel antihypertensive peptides from egg proteins by QSAR and bioinformatics. FOOD RES INT. 2010;43(5):1371–1378. [Google Scholar]
  • 26. Sagardia I, Roa-Ureta H R, Bald C. A new QSAR model, for angiotensin I-converting enzyme inhibitory oligopeptides. Food Chem. 2013;130:1370–1376. [DOI] [PubMed] [Google Scholar]
  • 27. Zhong M, Chong Y, Nie X, Yan A, Yuan Q. Prediction of sweetness by multilinear regression analysis and support vector machine. J Food Sci. 2013;78(9):S1445–1450. 10.1111/1750-3841.12199 [DOI] [PubMed] [Google Scholar]
  • 28. Peng W, Zhong J, Yang J, Ren Y, Xu T, Xiao S, et al. The artificial neural network approach based on uniform design to optimize the fed-batch fermentation condition: application to the production of iturin A. Microb Cell Fact. 2014;13(1):54 10.1186/1475-2859-13-54 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Nedjar-Arroume N, Dubois-Delval V, Adje EY, Traisnel J, Krier F, Mary P, et al. Bovine hemoglobin: An attractive source of antibacterial peptides. Peptides. 2008;29:969–977. 10.1016/j.peptides.2008.01.011 [DOI] [PubMed] [Google Scholar]
  • 30. Nedjar-Arroume N, Dubois-Delval V, Miloudi K, Daoud R, Krier F, Kouach M, et al. Isolation and characterization of four antibacterial peptides from bovine hemoglobin. Peptides. 2006;27:2082–2089. [DOI] [PubMed] [Google Scholar]
  • 31. Catiau L, Traisnel J, Delval-DuboiS V, Chihib N- E, Guillochon D, Nedjar-Arroume N. Minimal antimicrobial peptidic sequence from hemoglobin alpha-chain: KYR. Peptides. 2011;32:633–638. 10.1016/j.peptides.2010.12.016 [DOI] [PubMed] [Google Scholar]
  • 32. Catiau L, Traisnel J, Chihib N-E, Flem GL, Blanpain A, Melnyk O, et al. RYH A minimal peptidic sequence obtained from beta-chain hemoglobin exhibiting an antimicrobial activity. Peptides. 2011;32:1463–1468. 10.1016/j.peptides.2011.05.021 [DOI] [PubMed] [Google Scholar]
  • 33. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. 1988;85(24):9386–9390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. He R, Aluko RE, Ju X-R. Evaluating Molecular Mechanism of Hypotensive Peptides Interactions with Renin and Angiotensin Converting Enzyme. PloS one. 2014;9(3):e91051 10.1371/journal.pone.0091051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Watermeyer JM. Structural determinants of the domain-selectivity of novel inhibitors of human testis angiotensin-converting enzyme: University of Cape Town; 2008.
  • 36. Donkor ON, Henriksson A, Singh TK, Vasiljevic T, Shah NP. ACE-inhibitory activity of probiotic yoghurt. Int Dairy J. 2007;17(11):1321–1331. [Google Scholar]
  • 37. Guang C, Phillips RD. Plant food-derived Angiotensin I converting enzyme inhibitory peptides. J Agric Food Chem. 2009;57(12):5113–5120. 10.1021/jf900494d [DOI] [PubMed] [Google Scholar]
  • 38. Gómez-Ruiz JÁ, Taborda G, Amigo L, Recio I, Ramos M. Identification of ACE-inhibitory peptides in different Spanish cheeses by tandem mass spectrometry. Eur Food Res Technol. 2006;223(5):595–601. [Google Scholar]
  • 39. Majumder K, Wu J. Angiotensin I converting enzyme inhibitory peptides from simulated in vitro gastrointestinal digestion of cooked eggs. J Agric Food Chem. 2009;57(2):471–477. 10.1021/jf8028557 [DOI] [PubMed] [Google Scholar]
  • 40. Hernández-Ledesma B, Quirós A, Amigo L, Recio I. Identification of bioactive peptides after digestion of human milk and infant formula with pepsin and pancreatin. Int Dairy J. 2007;17(1):42–49. [Google Scholar]
  • 41. Hasan F, Kumada Y, Hashimoto N, Katsuda T, Terashima M, Katoh S. Fragmentation of angiotensin-I converting enzyme inhibitory peptides from bonito meat under intestinal digestion conditions and their characterization. Food Bioprod Process. 2006;84(2):135–138. [Google Scholar]
  • 42. Gómez-Ruiz JÁ, Ramos M, Recio I. Identification of novel angiotensin-converting enzyme-inhibitory peptides from ovine milk proteins by CE-MS and chromatographic techniques. Electrophoresis. 2007;28(22):4202–4211. [DOI] [PubMed] [Google Scholar]
  • 43. Hernandez-Ledesma B, Ramos M, Recio I, Amigo L. Effect of beta-lactoglobulin hydrolysis with thermolysin under denaturing temperatures on the release of bioactive peptides. J Chromatogr A. 2006;1116(1–2):31–37. [DOI] [PubMed] [Google Scholar]
  • 44. Wu H, He H-L, Chen X-L, Sun C-Y, Zhang Y-Z, Zhou B-C. Purification and identification of novel angiotensin-I-converting enzyme inhibitory peptides from shark meat hydrolysate. PROCESS BIOCHEM. 2008;43(4):457–461. [Google Scholar]
  • 45. Hyoung Lee D, Ho Kim J, Sik Park J, Jun Choi Y, Soo Lee J. Isolation and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from the edible mushroom Tricholoma giganteum. Peptides. 2004;25(4):621–627. [DOI] [PubMed] [Google Scholar]
  • 46. Contreras MdM, Carrón R, Montero MJ, Ramos M, Recio I. Novel casein-derived peptides with antihypertensive activity. Int Dairy J. 2009;19(10):566–573. [Google Scholar]
  • 47. Muguruma M, Ahhmed AM, Katayama K, Kawahara S, Maruyama M, Nakamura T. Identification of pro-drug type ACE inhibitory peptide sourced from porcine myosin B: Evaluation of its antihypertensive effects in vivo. Food Chem. 2009;114(2):516–522. [Google Scholar]
  • 48. Ren Y, Wan D-G, Lu X-m, Chen L, Zhang T-e, Guo J-L. Isolation and characterization of angiotensin I-converting enzyme inhibitor peptides derived from porcine hemoglobin. Sci Res Essays. 2011;6(30):6262–6269. [Google Scholar]
  • 49. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4–17. [DOI] [PubMed] [Google Scholar]
  • 50. Shen Q, Jiang J-H, Jiao C-X, Shen G-l, Yu R-Q. Modified particle swarm optimization algorithm for variable selection in MLR and PLS modeling: QSAR studies of antagonism of angiotensin II antagonists. EUR J PHARM SCI. 2004;22(2):145–152. [DOI] [PubMed] [Google Scholar]
  • 51. Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci. 1987;27(1):21–35. [DOI] [PubMed] [Google Scholar]
  • 52. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43(20):3714–3717. [DOI] [PubMed] [Google Scholar]
  • 53. Jalali-Heravi M, Asadollahi-Baboli M, Shahbazikhah P. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg—Marquardt algorithm. Eur J Med Chem. 2008;43(3):548–556. [DOI] [PubMed] [Google Scholar]
  • 54. Liu J, Yu Z, Zhao W, Lin S, Wang E, Zhang Y, et al. Isolation and identification of angiotensin-converting enzyme inhibitory peptides from egg white protein hydrolysates. Food Chem. 2010;122(4):1159–1163. [Google Scholar]
  • 55. Yu Z, Liu B, Zhao W, Yin Y, Liu J, Chen F. Primary and secondary structure of novel ACE-inhibitory peptides from egg white protein. Food Chem. 2012;133(2):315–322. [DOI] [PubMed] [Google Scholar]
  • 56. Yu Z, Zhao W, Liu J, Lu J, Chen F. QIGLF, a novel angiotensin I-converting enzyme-inhibitory peptide from egg white protein. J Sci Food Agric. 2011;91(5):921–926. 10.1002/jsfa.4266 [DOI] [PubMed] [Google Scholar]
  • 57. Yu Z, Yin Y, Zhao W, Yu Y, Liu B, Liu J, et al. Novel peptides derived from egg white protein inhibiting alpha-glucosidase. Food Chem. 2011;129(4):1376–1382. 10.1021/jf1035004 [DOI] [PubMed] [Google Scholar]
  • 58. Liu B. The quantitative structure activity relationships of angiotensin converting enzyme inhibitor peptide from egg white. Changchun: Jilin University; 2013. [Google Scholar]
  • 59. Ni H, Li L, Liu G, Hu S- Q. Inhibition mechanism and model of an angiotensin I-converting enzyme (ACE)-inhibitory hexapeptide from yeast (Saccharomyces cerevisiae). PloS one. 2012;7(5):e37077 10.1371/journal.pone.0037077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Natesh R, Schwager SLU, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. nature. 2003;421(30):551–554. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. The MSE of different structure of BPNN model.

(DOC)

S2 Table. The coefficient of determination (square of pearson correlation coefficient) of different structure of BPNN models.

(DOC)

Data Availability Statement

All relevant data are within the paper and its Supporting Information files.


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES